Market access ensures that innovative therapies not only exist but reach the patients who need them. Achieving this requires a strategic approach that begins early in development. Access teams translate clinical data into real-world value for payers and healthcare systems, but demonstrating value can be challenging due to limited evidence, weak narratives, or difficulty proving benefit over current options.   

In this landscape, patient-informed evidence is a strategic asset that facilitates product access and launch. This article defines patient experience data, explores its strategic value in market access and product launch, and outlines key methods for gathering it.  

Defining Patient Experience Data 

Patient experience data, also known as patient-informed evidence, consist of valuable qualitative and quantitative information that patients provide based on their healthcare experiences, preferences, perceptions, and behaviors. These insights, obtained through a range of methods, enable healthcare providers, pharmaceutical companies, payers, and policymakers to gain a clearer understanding of what patients need, expect, and value in their treatment and care, ultimately resulting in faster treatment access.  

Patient experience data include, among other insights: 

• Patient experiences and journeys: details about how patients perceive their interactions within the healthcare system, including diagnosis, treatment, communication with providers, adherence, behaviors, and barriers to care.  
• Patient preferences: information on what aspects of treatment and diagnosis patients prioritize, such as convenience, effectiveness, side effects, and cost. These preferences are increasingly influential in health technology assessment (HTA), with 82.5% of surveyed HTA bodies and related organizations formally integrating patient preference data into their review processes. 
• Patient-reported outcomes: data directly reported by patients regarding their health condition and treatment impact, including symptoms, quality of life, functional status, and overall health.  
• Psychosocial and emotional insights: understanding of the emotional, mental, and social factors shaping patients’ healthcare experiences and their effects on treatment decisions.  

Patient experience data can be gathered through both quantitative and qualitative approaches. For example, surveys and patient preference studies can collect structured, quantitative feedback on experiences and treatment outcomes. Standardized patient-reported outcome measures allow patients to evaluate aspects like pain, functionality, and quality of life. Meanwhile, qualitative methods such as patient interviews and patient advisory board meetings provide rich, detailed insights into patient attitudes, needs, and challenges.  

Strategic Value in Market Access 

Incorporating patient insights and evidence early and throughout the development process provides companies with a competitive advantage. These insights are transformative in how products are developed, positioned, and accessed: 

• Accelerated access: patient-informed protocols are more likely to resonate with regulators and decision-makers, increasing the efficiency of the approval process. Clinical outcomes that reflect real-world priorities, like symptom relief or treatment convenience, carry more weight with payers and HTA bodies.  
• Improved product fit: understanding treatment experiences and patient priorities helps shape development plans that align with unmet needs and deliver better real-life outcomes.  
• Enhanced value demonstration: payers are increasingly demanding evidence that products deliver meaningful value. Patient-informed evidence strengthens value dossiers by highlighting how clinical outcomes are directly impacting quality of life and addressing unmet needs.  
• Informed launch strategy: insights into patient language, perceptions, and expectations guide brand communication and stakeholder engagement, increasing uptake and overall treatment adherence.  

Methods of Gathering Patient Insights 

To fully benefit from patient input, companies must implement structured and robust methods of gathering insights. Best practices include:

Patient Advisory Boards (PABs) 

PABs involve curated groups of patients and caregivers who provide feedback on disease impact, unmet needs, trial design and relevance of endpoints, testing of (blind) target product profiles, and communication strategies. These boards promote two-way dialogue and give companies direct access to patients’ real-life expertise that they can report in access dossiers. Effective PABs require thoughtful planning, ethical oversight, and inclusion of diverse perspectives to avoid bias.  

Qualitative Interviews

One-on-one interviews allow for in-depth exploration of individual experiences. These are particularly useful when investigating sensitive topics or capturing nuanced aspects of the patient journey that may not surface in group settings, such as the emotional journey and real-life challenges with the disease and/or treatment intake/adherence.

Surveys

Quantitative methods such as structured surveys help collect generalized data across large patient populations. They can measure the burden of disease, treatment satisfaction, quality of life, willingness to pay, and patient-reported outcomes, all of which inform value frameworks and market access submissions.  

Patient Journey Mapping

This process visualizes the full trajectory of a patient’s healthcare experience, from symptoms and diagnosis through treatment and follow-up. Mapping highlights pain points, decision-making moments, and opportunities for support or intervention. 

Digital Listening and Online Communities 

Patients frequently share unfiltered feedback in digital forums and social media. Analyzing these sources provides real-time access to trends, concerns, and experiences that traditional research might miss. Digital tools also allow continuous monitoring over time.  

Conclusion

Patient experience data are essential for ensuring therapies meet real-world needs and reach the patients who benefit most. By leveraging methods like PABs, interviews, surveys, patient journey mapping, and digital listening, life science companies can gather robust patient insights that strengthen value demonstration, support pricing and reimbursement decisions, and accelerate market access. Aligning more closely with patients can lead to better outcomes, increased payer confidence, and more successful product launches. 

How Alira Health Can Help

Our Patient, Access and Evidence Solutions team has direct patient engagement and advocacy expertise and is experienced in gathering valuable patient experience data that support our clients’ evidence packages and meet payer and regulator needs. This cross-functional team can help shape your access and value strategy, present a compelling, patient-informed story about the burden of illness and unmet needs, and demonstrate the true value of treatments through improved quality of life for patients. The result is an increased likelihood of an optimal price and reimbursement process.